Pharm Flashcards
What are the DMARDs for treating RA?
Methotrexate, hydroxychloroquine, leflunomide, sulfasalazine
What are DMARDs?
Drugs from many classes with no common properties other than the ability to improve inflammatory symptoms and slow the progression of joint erosions.
Methotrexate MOA in immunosupression
Inhibition of AICAR transformylase, which catalyzes the last step in biosynthesis of inosine monophosphate. Inhibition leads to AICA riboside accumulation so you end up with more adenosine around and that inhibits lymphocyte proliferations and suppresses secretion of IL1, inf-gamma, and tnf, and all sorts of other good stuff
Methotrexate metabolism
When it enters cell methotrexate undergoes polyglutamation which serves to retain drug intercellularly. Hepatic metabolism and enterohepatic recirculation
Methotrexate elimination
Primarily via the kidney, competition with weak acids and prebenecid
Contraindications to methotrexate
Pregnancy, HIV
Adverse effects of methotrexate
Bone marrow suppression, pulmonary toxicity, malignant lymphomas, dermatological rxns, GI toxicity (in pts with PUD or ulcerative colitis, with NSAIDs).
Don’t vaccinate while on methotrexate
Monitoring parameters for methotrexate
CBC with differential, LFTs, serum creatinine/BUN, serum uric acid
What is sulfasalazine?
Oral drug used in pts who respond inadequately to salicylates or other NSAIDs. Metabolized to active components sulfapyridine and masalamine by bacteria in colon
Sulfasalazine MOA
Anti-inflammatory action results from mesalamine inhibiting prostaglandin and leukotriene production
Sulfasalazine elimination
Renal- caution in pts with renal dysfunction
Sulfasalazine contraindications
Hypersensitivity to 5-aminosalicylate, salicylate, or sulfonamide drugs
Sulfasalazine toxicities
Potentially fatal blood dyscrasias
Monitoring parameters for sulfasalazine
CBC w/diff, LFTs, serum creatinine/BUN, urinalysis
Leflunomide MOA
Activity via metabolite A77 1726, inhibiting dihydroorotate dehydrogenase in mitochondria. T and B lymphocyte cell cycle progression arrested and collaborative interaction interrupted. Immunoglobulin production also suppressed.
Leflunomide elimination
A77 1726 exhibits uricosuric effect. Elimination in feces and other conjugated.
Leflunomide toxicities
Hepatic toxicity with chronic use (caution in alcoholics)
Contraindications of leflunomide
Severe immunodeficiency, bone marrow dyscrasia, or uncontrollably infection
Pregnancy
Heavy alcohol use
Monitoring of leflunomide
CBC w/diff, LFTs, pregnancy testing, serum electrolytes
Hydroxychloroquine MOA
Increases intracellular vacuole pH so MHC II proteins can’t be assembled. So the drug diminishes formation of peptide-MHC protein complexes required to stimulate CD4 t cells
Hydroxychloroquine elimination
Extensive and slow renal elimination after partial hepatic metabolism
Contraindications of hydroxychloroquine
Ocular disease, alcoholism
Toxicity of hydrochloroquine
Blood dyscrasia, CNS (polyneuritis, ototoxicity, seizures, and neuromyopathy)
Abatacept administration
IV/SC
Abatacept structure
Fusion protein: human CTLA4/IgG1 Fc fragment
Abatacept MOA
Binds CD80 and CD86, prevents T-cell co-stimulatory signal engaging with CD28
Adalimumab administration
SC
Adalimumab structure
TNF- alpha monoclonal antibody
Adalimumab MOA
Binds TNF-alpha, blocks it’s interaction with the p55 and p75 cell surface receptors
Anakinra administration
SC
Ankinra structure
Recombinant human interleukin-1 receptor antagonist (IL-1Ra)
Anakinra MOA
Competitively inhibits IL-1 alpha and IL-1 beta binding to interleukin-1 type 1 receptor (IL-1R1)